---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053949"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:00:12.606161+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs

## Summary
- Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.
- Ligand has option to invest additional $25M on same terms; Agenus may syndicate up to $125M more, bringing total potential to $200M.
- Warrant issued to Ligand for 867,052 shares of AGEN common stock at $17.30, exercisable until May 6, 2029.
- Funds will support BOT/BAL confirmatory Phase 3 trial in r/r MSS CRC liver metastases-negative and launch readiness activities.
- Covered programs include BMS-986442, AGEN2373 (Gilead), INCAGN2385/2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen).

## SEC filing metadata
- accession: 0000950170-24-053949
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/0000950170-24-053949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/agen-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053949
- JSON: https://secwatch.observer/filing/0000950170-24-053949.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053949.txt

## Key facts
- Material Agreements
  AGENUS INC entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $75 million (effective 2024-05-06).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Ligand Pharmaceuticals Incorporated
  - Value: $75 million
  - Effective: 2024-05-06
  source text: On May 6, 2024, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/0000950170-24-053949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.